

Genomics and Health Information Technology Systems: Exploring the Issues

Challenges in Standards Development

Debra G.B. Leonard, MD, PhD
Weill Cornell Medical College



Molecular Pathologist Perspective

- Genomics
- Information Technology
- Quality



Genomics

- Past
 - Single gene tests for single gene genetic disease & cancer
- Present
 - Single gene, gene panel, gene expression, CNVs for genetics & cancer
- Future (very near!) = **Genomics**
 - Large gene sets, whole exome, genome, transcriptome, microbiome for most disease states
 - Driven by lower cost of sequencing, but IT lags



Genomics

- Every person has a unique genome
- Each patient's genomic sequence will be a new test interpretation: never seen before
- This will not change with more research
- Requires significant molecular genetic expertise
- Requires as much information as possible to interpret individual genomes (Software & Variant Database)
 - Significance analysis of variants
 - Previous knowledge of sequence variants and phenotype
 - Clinical information on individual



Genomics & Evidence

- Evidentiary standards currently very high
 - USPSTF, EGAPP, AHRQ, etc
 - Population-based evidence
 - Not many molecular tests found useful
- How apply evidence standards to individual unique patient genome interpretation?
 - Single gene variations with known phenotypes →
 - Complexity of an entire genome (pathways, modifiers, etc)



Genomics Testing Process

- Informed consent (extent of interpretation, database entry, reinterpretation)
- Sequence data generation & analysis
 - Quality assessment of sequence data (coverage, variant frequency, etc)
 - Alignment to reference sequence
 - Variant calling compared to reference sequence
- Variant Interpretation
 - Comparison to databases (OMIM, COSMIC, dbSNP, 1000 Genomes, ENCODE, etc.)
 - Evolutionary conservancy analysis
 - Protein structural analysis
 - Pathway analysis
 - Integration with clinical , phenotype & family data
- Report in Laboratory Information System
- Transfer report from LIS to EHR and PHR for genomics reports
- Store sequence/variants & reinterpret VS sequence again with new technology



National/International Variant Database

- Define inclusion criteria
 - Informed consent
 - Quality of sequence (coverage, %, etc)
 - Genotype-phenotype data
- Curation of database
 - Assure quality of sequence and phenotype
 - Assign level of evidence (pathogenic, probably pathogenic, non-pathogenic, etc)
 - Update based on new knowledge
- Accessibility & interoperability
- Public engagement



Genomic Testing & Quality

- Sequence Quality
 - Standards will vary by purpose of test
 - Capture, coverage of genome, coverage of sequence, variant frequency, error rate



Constitutional vs Cancer

Constitutional	Cancer
Blood or buccal specimen	Tissue (handling & selection)
Sequence does not change for person but can by tissue	Repeat sequence with relapse
Lower coverage (30X)	Higher coverage (>500X)



Cancer Sequencing

Cancer Sequencing	Coverage Handicap
Initial depth of sequencing coverage	100X (1)
Heterozygous mutation	50X (0.5)
Tumor cellularity	100% (best possible, e.g. blood): 50X (0.5) 20% (conservative): 10X (0.1)
Tumor heterogeneity	Only 1 clone (best possible): 10X (0.1) 3 clones (low estimate): 3.3X (0.033) 10 clones (conservative estimate): 1X

Cancer sequencing requires 500X coverage for 97% confidence

John Pfeifer, MD, PhD, Washington University



Genomic Testing & Quality

- Sequence Quality
 - Standards will vary by purpose of test
 - Capture, coverage of genome, coverage of sequence, variant frequency, error rate
- Bioinformatics Quality
 - Different algorithms gives different results
 - Validate, but how know what gives the “right” answer?
 - Version documentation



Genomic Testing & Quality

- Sequence Quality
 - Standards will vary by purpose of test
 - Capture, coverage of genome, coverage of sequence, variant frequency, error rate
- Bioinformatics Quality
 - Different algorithms gives different results
 - Validate, but how know what gives the “right” answer?
 - Version documentation
- Phenotype Quality (EHR)
 - Race & ethnicity: reported or based on genome?
 - Family history standards
 - Disease definition standards
 - Environmental exposures
 - Formatted EHRs, not free text



Clinical Use of Sequence Results

- Clinical Decision Support Tools
 - Given complexity of genome interpretation, where deliver clinical usefulness information: report vs clinical information system vs physician knowledge?
 - Each patient's genome is unique, so can MDs act on non-population based evidence?
 - What level of evidence needed to change patient care management? USPSTF? EGAPP? AHRQ? Medical science?
 - Even if agree on Decision Support Tools that are clinically valid, how implement in all clinical IT systems?
- Personal Health Record Support Tools
 - How communicate results at 6th grade level?




Genomics & Information Technology

- Interoperability essential
 - Genomic testing
 - Results to EHR/PHR
 - Data to National Variant Database
- Formatted data in EHRs
- Standard gene nomenclature
- Documentation of software & database versions used for interpretation, as knowledge changes



“Genomics” IT System



Other Issues

- Informed consent
 - Extent of genome interpretation, retention, re-interpretation
- Record retention
 - Store raw sequence data, all variants or reported variants?
 - Cost of sequence data storage vs resequence with improved technology in future
- Payment
 - No FDA approved tests; performed in CLIA-certified labs
 - No CPT codes for technical or interpretive components of testing OR for reinterpretation, if store sequence
 - Third party payer reimbursement?
- Public engagement AND family engagement issues

